EGFL7 and glioma: A combination of both antibodies might be applied to reduce the doses of bevacizumab and/or chemotherapeutics to increase the well‐being of patients suffering from glioma during their treatment, which is supported by our chemotherapy regimen combining TMD with anti‐VEGF‐ and anti‐EGFL7 treatment in experimental glioma.